Help Guide Disclaimer Contact us Login
  Advanced SearchBrowse




Journal Article

Adenosine triphosphate inhibits cytokine release from lipopolysaccharide-activated microglia via P(2)y receptors


Schubert,  P.
Emeritus Group: Neuromorphology / Kreutzberg, MPI of Neurobiology, Max Planck Society;

There are no locators available
Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available

Ogata, T., Chuai, M., Morino, T., Yamamoto, H., Nakamura, Y., & Schubert, P. (2003). Adenosine triphosphate inhibits cytokine release from lipopolysaccharide-activated microglia via P(2)y receptors. Brain Research, 981(1-2), 174-183.

Cite as:
Microglial proliferation. and activation have been reported to occur after several central nervous system injuries. In this study, we tested the effects of adenosine triphosphate (ATP) on cultured microglia obtained from the spinal cord of rat embryos. The amounts of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta and interleukin 6 released from the microglia, which were stimulated by lipopolysaccharide (LPS; 100 ng/ml), were inhibited by the simultaneous addition of ATP in a dose dependent manner (10-300 muM). We examined the effect of several endogenous purines (ATP, ADP, CTP, UDP, UTP) and P(2)y receptor agonists (ADPbetaS and 2-methylthio-ATP) on LPS-induced TNF-alpha release. Th rank order of inhibitory potency of endogenous purines on TNF-alpha release was: ATP>ADP>>UTP> UDP>CTP. The latter three were much less potent than the former two. The addition of 10 muM 2-methylthio-ATP showed a potency similar to 100 muM ATP. The addition of ADPbetaS, however, showed less effect. These endogenous purines and selective ATP receptor agonists showed a similar inhibitory effect in their rank order on LPS-induced interleukin 6 release. We demonstrate that ATP inhibits cytokine release from LPS-activated microglia via metabotropic receptors. The application of P(2)y receptor agonists might be considered as a pharmacological treatment of several pathological conditions of the spinal cord, including toxic immunoreactions. (C) 2003 Elsevier B.V. All rights reserved.